Here, we are going to share Piramal Pharma Share Price Target 2025 to 2040 on the basis of its fundamental and technical analysis.
Piramal Pharma Ltd (PPL), a part of the Piramal Group, is a well-known player in the pharmaceutical sector, offering a diverse range of products and services through its integrated manufacturing capabilities across 15 global facilities.
With a global distribution network spanning over 100 countries, the company serves the needs of both innovators and generic pharmaceutical companies.
It includes business segments such as Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and India Consumer Healthcare, positioning itself as a significant contributor to the global healthcare industry.
Piramal Pharma Company Overview
- Established Year: 1988
- Headquarters: Mumbai, Maharashtra, India
- Business: Manufacturing and distributing pharmaceutical products, Contract Development and Manufacturing Organisation (CDMO), hospital generics, and consumer healthcare products.
- Growth: The company has shown consistent revenue growth with an expanding global footprint, focusing on enhancing its service capabilities and entering new markets.
- Employees: Over 5,000
- Location: Operates across India and in several international markets.
- Markets Served: Global presence in over 100 countries, with key markets in North America, Europe, and Asia.
Piramal Pharma Share Key Information
| Company Name | Piramal Pharma Ltd |
| Headquarters | Mumbai, Maharashtra |
| Sectors | Pharmaceutical |
| Market Cap | ₹ 29,060.40 Cr. |
| No. of Shares | 132.57 Cr. |
| Book Value | ₹51.09 |
| Dividend Yield | 0.05% |
| ROCE | 8.33% |
| ROE | 6.55% |
| Face Value | ₹10 |
| Sales Growth | 27.50% |
| Profit Growth | 462.91% |
Piramal Pharma Business Sector
Piramal Pharma Ltd operates across three main segments:
- Piramal Pharma Solutions (PPS): Provides end-to-end development and manufacturing solutions to pharmaceutical companies globally.
- Piramal Critical Care (PCC): Specializes in complex hospital generics, including inhalation anesthetics and injectable pain management therapies.
- India Consumer Healthcare: Focuses on over-the-counter products catering to the self-care segment in India.
Board Members
- Ajay Piramal: Chairman
- Nandini Piramal: Executive Director
- Peter DeYoung: Executive Director
- Vandana Burman: Independent Director
- Vijay Shah: Non-Executive Director
- Harsha Raghavan: Non-Executive Director
Piramal Pharma Share Quarterly Results
| PARTICULARS | Mar 2024 | Jun 2024 |
|---|---|---|
| Net Sales | 1,525.30 | 1,063.20 |
| Total Expenditure | 1,135.66 | 911.57 |
| Operating Profit | 389.64 | 151.63 |
| Other Income | 53.19 | 36.76 |
| Interest | 27.66 | 24.88 |
| Depreciation | 52.50 | 51.85 |
| Exceptional Items | 0 | 0 |
| Profit Before Tax | 362.67 | 111.66 |
| Tax | 89.59 | 26.39 |
| Profit After Tax | 273.08 | 85.27 |
| Adjusted EPS (Rs) | 2.06 | 0.64 |
Piramal Pharma Company Profits and Losses
| PARTICULARS | Mar 2023 | Mar 2024 |
|---|---|---|
| Net Sales | 3,443.22 | 4,390.11 |
| Total Expenditure | 3,345.69 | 3,790.71 |
| Operating Profit | 97.53 | 599.40 |
| Other Income | 341.07 | 220.58 |
| Interest | 115.87 | 107.10 |
| Depreciation | 192.08 | 205.26 |
| Exceptional Items | -6.96 | 0 |
| Profit Before Tax | 123.69 | 507.62 |
| Tax | 54.19 | 116.40 |
| Net Profit | 69.50 | 391.22 |
| Adjusted EPS (Rs.) | 0.57 | 2.96 |
Piramal Pharma Share Price Target 2025-2040
| Year | Initial Target | Year-End Target |
|---|---|---|
| 2025 | ₹232 | ₹250 |
| 2026 | ₹252 | ₹271 |
| 2027 | ₹273 | ₹301 |
| 2028 | ₹302 | ₹339 |
| 2029 | ₹344 | ₹379 |
| 2030 | ₹382 | ₹421 |
| 2035 | ₹545 | ₹571 |
| 2040 | ₹721 | ₹782 |
Piramal Pharma Share Price Target 2025
| Year/Month | Predicted Target |
|---|---|
| January 2025 | ₹232 |
| February 2025 | ₹236 |
| March 2025 | ₹238 |
| April 2025 | ₹236 |
| May 2025 | ₹239 |
| June 2025 | ₹242 |
| July 2025 | ₹246 |
| August 2025 | ₹247 |
| September 2025 | ₹251 |
| October 2025 | ₹248 |
| November 2025 | ₹246 |
| December 2025 | ₹250 |
Piramal Pharma Share Price Target 2026
| Year/Month | Predicted Target |
|---|---|
| January 2026 | ₹252 |
| February 2026 | ₹255 |
| March 2026 | ₹256 |
| April 2026 | ₹261 |
| May 2026 | ₹259 |
| June 2026 | ₹262 |
| July 2026 | ₹265 |
| August 2026 | ₹268 |
| September 2026 | ₹269 |
| October 2026 | ₹272 |
| November 2026 | ₹268 |
| December 2026 | ₹271 |
Piramal Pharma Share Price Target 2027
| Year/Month | Predicted Target |
|---|---|
| January 2027 | ₹273 |
| February 2027 | ₹277 |
| March 2027 | ₹275 |
| April 2027 | ₹278 |
| May 2027 | ₹282 |
| June 2027 | ₹286 |
| July 2027 | ₹285 |
| August 2027 | ₹291 |
| September 2027 | ₹292 |
| October 2027 | ₹295 |
| November 2027 | ₹297 |
| December 2027 | ₹301 |
Piramal Pharma Share Price Target 2028
| Year/Month | Predicted Target |
|---|---|
| January 2028 | ₹302 |
| February 2028 | ₹307 |
| March 2028 | ₹309 |
| April 2028 | ₹315 |
| May 2028 | ₹311 |
| June 2028 | ₹317 |
| July 2028 | ₹322 |
| August 2028 | ₹327 |
| September 2028 | ₹331 |
| October 2028 | ₹329 |
| November 2028 | ₹335 |
| December 2028 | ₹339 |
Piramal Pharma Share Price Target 2029
| Year/Month | Predicted Target |
|---|---|
| January 2029 | ₹344 |
| February 2029 | ₹347 |
| March 2029 | ₹339 |
| April 2029 | ₹351 |
| May 2029 | ₹356 |
| June 2029 | ₹361 |
| July 2029 | ₹359 |
| August 2029 | ₹365 |
| September 2029 | ₹371 |
| October 2029 | ₹377 |
| November 2029 | ₹375 |
| December 2029 | ₹379 |
Piramal Pharma Share Price Target 2030
| Year/Month | Predicted Target |
|---|---|
| January 2030 | ₹382 |
| February 2030 | ₹379 |
| March 2030 | ₹386 |
| April 2030 | ₹391 |
| May 2030 | ₹388 |
| June 2030 | ₹395 |
| July 2030 | ₹399 |
| August 2030 | ₹401 |
| September 2030 | ₹405 |
| October 2030 | ₹409 |
| November 2030 | ₹413 |
| December 2030 | ₹421 |
Piramal Pharma Share Price Target 2035
| Year/Month | Predicted Target |
|---|---|
| January 2035 | ₹545 |
| April 2035 | ₹549 |
| July 2035 | ₹555 |
| October 2035 | ₹562 |
| December 2035 | ₹571 |
Piramal Pharma Share Price Target 2040
| Year/Month | Predicted Target |
|---|---|
| January 2040 | ₹721 |
| April 2040 | ₹729 |
| July 2040 | ₹756 |
| October 2040 | ₹769 |
| December 2040 | ₹782 |
Piramal Pharma Shareholding Pattern
| Terms | Percentage |
|---|---|
| Promoters | 34.95% |
| FIIs | 31.41% |
| DIIs | 12.96% |
| Others | 0% |
| Public | 20.69% |
Piramal Pharma Company Competitors
- Dr Reddy’s Lab
- Laurus Lab
- Natco Pharma
- Emcure Pharma
- Lupin Ltd
Bull Case of Piramal Pharma (Reasons to Invest)
Expanding Global Footprint: With operations in over 100 countries, Piramal Pharma has a strong global presence that can be leveraged for further growth.
Strategic Partnerships: Collaborations with global market leaders and a joint venture with Allergan strengthen its position in specialized markets like ophthalmology.
Focus on High-Growth Segments: Increased investments in consumer healthcare and hospital generics could drive higher margins and growth.
Bear Case of Piramal Pharma (Risks Involved)
Volatility in Profit Margins: Historical fluctuations in profit margins and profitability can create uncertainty among investors.
Debt Levels: High borrowings and associated interest expenses could strain financial stability and limit the company’s growth opportunities.
Regulatory Challenges: Being in the pharmaceutical sector, the company is exposed to regulatory risks, which can impact its operations and product launches.
Competitive Market: The pharmaceutical industry is highly competitive, with large multinational players dominating the market, which could impact Piramal’s market share.
Piramal Pharma Share Price Target: FAQ
What will be the target of Piramal Pharma Share for the year 2025?
By the end of the year 2025, its share price can reach ₹250.
What will be the target of Piramal Pharma Share for the year 2026?
By the end of the year 2026, its share price can reach ₹271.
What will be the target of Piramal Pharma Share for the year 2027?
By the end of the year 2027, its share price can reach ₹301.
What will be the target of Piramal Pharma Share for the year 2028?
By the end of the year 2028, its share price can reach ₹339.
What will be the target of Piramal Pharma Share for the year 2029?
By the end of the year 2029, its share price can reach ₹379.
What will be the target of Piramal Pharma Share for the year 2030?
By the end of the year 2030 its share price can reach ₹421.
What is the Current market cap of Piramal Pharma company?
At present the market cap of this company is ₹ 29060.40 Cr.
What is the NSE symbol of Piramal Pharma company?
The symbol of this company in NSE exchange is PPLPHARMA.
What is the BSE symbol of Piramal Pharma company?
The symbol of this company in BSE exchange is 543635.
